Lamivudine

HIV Infection

Lamivudine is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in adults and children. It helps decrease the amount of HIV in the body so the immune system can work better and reduces the risk of HIV-related complications.

Chronic Hepatitis B

This medication is also used to treat chronic hepatitis B, a long-term viral infection of the liver. It works by reducing the amount of the hepatitis B virus in the body and may help reduce liver inflammation and damage.

Important Considerations

Lamivudine does not cure HIV or hepatitis B. It also does not prevent the spread of these viruses to others through sexual contact or blood contamination. It must be used as part of a complete treatment plan as directed by a healthcare provider.

Mechanism of Action

Lamivudine belongs to a group of medicines known as nucleoside reverse transcriptase inhibitors (NRTIs). It works by interfering with the way certain viruses, specifically the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV), reproduce in the body.

How it Stops Viral Replication

To multiply, these viruses use an enzyme called reverse transcriptase to create new copies of their genetic material (DNA). Lamivudine is designed to mimic the natural building blocks that the virus uses to construct this DNA. When the virus attempts to build new DNA, it incorporates lamivudine into the chain. Because lamivudine is slightly different from a natural building block, it acts as a chain terminator, stopping the DNA strand from being completed.

Effects on the Body

• Viral Load Reduction: By preventing the virus from making copies of itself, the medication reduces the total amount of the virus (the viral load) in the bloodstream.
• Immune Support: In patients with HIV, lowering the viral load helps the immune system recover and function more effectively.
• Liver Protection: In patients with chronic hepatitis B, reducing the virus can help decrease inflammation and damage to the liver.

While lamivudine helps manage these conditions by slowing viral growth, it is not a cure for HIV or hepatitis B. It must be taken consistently to keep the virus from multiplying.

Common Side Effects

Commonly reported side effects of lamivudine include:

• Headache
• Nausea and vomiting
• Diarrhea
• Fatigue or a general feeling of being unwell
• Cough or nasal symptoms
• Muscle or joint pain
• Insomnia or sleep disturbances

Serious Side Effects

Seek medical attention immediately if you notice any of the following:

• Lactic acidosis: This is a serious buildup of acid in the blood. Symptoms include extreme weakness, unusual muscle pain, trouble breathing, stomach pain with nausea and vomiting, feeling cold, or feeling dizzy or lightheaded.
• Liver issues: Symptoms may include yellowing of the skin or eyes, dark-colored urine, light-colored bowel movements, or loss of appetite.
• Pancreatitis: Severe pain in the upper stomach that may spread to the back.
• Immune system changes: The immune system may become more active and attack previous or hidden infections.
• Fat redistribution: Changes in body fat, including increased fat in the trunk or neck and loss of fat from the limbs and face.

Children taking this medication may also experience ear infections or skin rashes.

Lactic Acidosis and Liver Enlargement

A serious condition called lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty liver have been reported with the use of lamivudine. These conditions can be life-threatening. Symptoms may include unusual tiredness, nausea, vomiting, stomach pain, or feeling cold.

Hepatitis B Flare-ups

In patients with chronic hepatitis B, stopping lamivudine can lead to a severe worsening of the infection. Liver function is typically monitored closely for several months after the medication is discontinued to watch for signs of a flare-up.

HIV Resistance

Because lamivudine is used to treat both HIV and hepatitis B, it is important to be tested for HIV before starting treatment for hepatitis B. If a person has undiagnosed or untreated HIV and takes the lower dose of lamivudine used for hepatitis B, the HIV virus may become resistant to treatment, making it harder to manage in the future.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has occurred in people taking lamivudine, particularly in children. This condition requires immediate medical attention if symptoms like severe stomach pain, nausea, or vomiting occur.

Immune Reconstitution Syndrome

In patients with HIV, the immune system may become more active after starting treatment. This can cause the body to react to previous or hidden infections that were already present.

Kidney Function

Lamivudine is cleared from the body through the kidneys. Individuals with decreased kidney function may require a different dosage to avoid the medication building up to unsafe levels.

Pregnancy

Lamivudine is frequently prescribed during pregnancy to treat HIV or chronic hepatitis B. When used for HIV, it is often part of a combination regimen intended to reduce the risk of passing the virus to the baby. Data from pregnancy registries have not shown a clear link between lamivudine and an increased risk of major birth defects compared to the general population. However, because every pregnancy is different, the decision to use this medication should be made in consultation with a healthcare professional.

Breastfeeding

Lamivudine is known to pass into breast milk. The recommendations for breastfeeding while taking lamivudine depend on the condition being treated:

• HIV: In many regions, healthcare providers advise against breastfeeding if you have HIV to prevent transmitting the virus to the infant through breast milk.
• Hepatitis B: The decision to breastfeed while taking lamivudine for hepatitis B involves weighing the benefits of breastfeeding against the potential exposure of the infant to the drug.

It is important to discuss feeding options and the potential risks to the infant with a doctor before starting or continuing breastfeeding while taking this medication.

Oral Tablets

Lamivudine is most commonly supplied as a tablet to be taken by mouth. There are different tablet strengths available, which are specifically labeled for either the treatment of chronic hepatitis B or HIV-1 infection.

Oral Solution

For children or individuals who have difficulty swallowing pills, lamivudine is available as an oral solution. This liquid form is provided in different concentrations depending on the condition being treated.

It is important to note that the products intended for hepatitis B contain a different amount of the active ingredient than those intended for HIV-1. These formulations are not interchangeable, and using the wrong product may lead to ineffective treatment. Patients should only use the specific formulation prescribed for their diagnosis.

FDA Approval and Indications

Lamivudine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of two distinct viral infections:

• HIV-1 Infection: It is used in combination with other antiretroviral agents for the treatment of HIV-1.
• Chronic Hepatitis B: It is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of viral replication and active liver inflammation.

Boxed Warnings

The FDA has issued several boxed warnings for lamivudine due to the risk of serious adverse reactions:

• Lactic Acidosis and Severe Liver Problems: There have been reports of lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty deposits (steatosis), which can be fatal.
• Exacerbations of Hepatitis B: Severe acute exacerbations of hepatitis B have been reported in patients who stop taking lamivudine. Liver function should be monitored closely for several months after treatment is discontinued.
• HIV Resistance: Using the lower dose of lamivudine intended for hepatitis B in patients with unrecognized or untreated HIV infection may lead to the HIV virus becoming resistant to the medication.
• Pancreatitis: Cases of pancreatitis have occurred, particularly in children with advanced HIV infection who have previously used other nucleoside analogues.

Patients should be tested for HIV infection before starting lamivudine for the treatment of hepatitis B to ensure the appropriate dosage and combination therapy are used.

Generic Availability

Lamivudine is available as a generic drug. Generic medications are typically less expensive than brand-name versions while providing the same therapeutic benefits.

Insurance and Pharmacy Factors

Most insurance plans, including Medicare, cover lamivudine. Your specific out-of-pocket costs will depend on your plan's coverage levels and copay requirements. Prices can also vary between different pharmacies.

Formulation and Dosage

The cost may be affected by the form of the medication prescribed, such as:

• Oral tablets
• Oral solution (liquid)

The dosage strength and the quantity of medication (such as a 30-day versus a 90-day supply) also play a role in determining the final price.

Financial Assistance

If you have difficulty affording your medication, you may be eligible for patient assistance programs. These programs are sometimes offered by manufacturers or non-profit organizations to help individuals with the cost of chronic treatments.